Clinical trials: Carrier of Viral Hepatitis Type B
Chronic Hepatitis, B Virus, Carrier of Viral Hepatitis Type B
Peg-interferon for Inactive Chronic Hepatitis B Carriers
Chronic Hepatitis B carriers (normal LFTs and viral load < 2 x 10^4 IU/ml are not recommended to be treated by guidelines as they are at low risk for complications.
- Trial name
- INACTIVE (NCT02992704)
- Testing
- Peginterferon Alfa-2A
- Where
- Singapore
- Volunteers
- 90 people
- Sponsor
- Seng Gee Lim
Hepatitis B
Follow-up of HBsAg Inactive Carriers Study
The definition of HBs antigen (HBsAg) inactive carrier status has evolved during time. We spoke first from HBsAg" healthy carrier ", then from " asymptomatic carrier ", last from HBsAg" inactive carrier ".
- Trial name
- PIBAC (NCT02247752)
- Testing
- inactive carrier
- Where
- 32 sites in France
- Volunteers
- 619 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Chronic Hepatitis B
Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg
Background: The HBsAg clearance rate in interferon-treated responders is significantly higher than that in lamivudine-treated responders, implying immune control is the key to HBsAg clearance.
- Trial name
- NCT01817725
- Testing
- HBV vaccine (Engerix B)
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Chang Gung Memorial Hospital
Chronic Hepatitis B
The Study on Optimal Treatment and Clinical Outcome of Chronic Hepatitis B Patients With Inactive Hypoviremia
Chronic hepatitis B seriously endangers the health of our people, especially the occurrence of HCC, which brings huge economic burden and life threat to our people. 84% - 92% of HCC in China is related to chronic HBV infection.
- Trial name
- NCT05357235
- Testing
- PEG-IFN
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Beijing Ditan Hospital
Colorectal Neoplasms
Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers
There has been no report on whether the patients with colorectal cancer who are also inactive Hepatitis B Carriers should receive Prophylactic Use or preemptive Use of an Anti-viral Drug Entecavir.
- Trial name
- NCT02777814
- Testing
- Entecavir
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Hepatitis B Virus
Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma
The purpose of this study is: 1. To establish and compare the diagnostic utilities for hepatocellular carcinoma (HCC) screening tests of (a) HS-AFP, (b) AFP + US,(c) AFP alone and (d) US alone (within HBV carriers between age 40…
- Trial name
- NCT00912847
- Volunteers
- 1,018 people
- Sponsor
- Chinese University of Hong Kong
Chronic Hepatitis B
Study on Clinical Program Optimization of Inactive Hepatitis B Surface Antigen (HBsAg) Carriers (IHCs)
A multicenter, randomized controlled trial design was used to select patients with chronic hepatitis B in the immune control phase (i.e.
- Trial name
- NCT05457920
- Testing
- continuous treatment, pulse therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Henan Provincial People's Hospital
Chronic Hepatitis B
Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B
Background: Hepatitis B is a viral infection of the liver. When the immune system tries to clear hepatitis B, it damages the liver. Eventually, the immune system gets exhausted fighting the virus.
- Trial name
- NCT03575208
- Testing
- hepatitis B immune globulin (HBIg), Pegylated interferon alfa (pegIFN)
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B, Neoplasms
A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers
Patients with non-lymphoma and non-leukaemia cancer who are also hepatitis B carriers will have a risk of hepatitis B reactivation during chemotherapy.
- Trial name
- NCT00516945
- Testing
- Lamivudine
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Hospital Authority, Hong Kong
Chronic Hepatitis B
Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus
This trial will study the effect of a polyherbal capsule in lowering the viral load of patients with chronic Hepatitis B infection and record the incidence of from Hepatitis B surface antigen elimination in 12 months
- Trial name
- NCT02899130
- Testing
- Polyherbal
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Composite Interceptive Med Science
Stomach Neoplasms
Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers
There has been no report on whether the patients with gastric cancer who are also inactive Hepatitis B carriers should receive prophylactic use or preemptive Use of an Anti-viral Drug Entecavir.
- Trial name
- NCT02777801
- Testing
- Entecavir
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Rheumatoid Arthritis, Hepatitis B Reactivation
Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients
Antiviral prophylaxis can prevent the risk of biologic agents-associated HBV reactivation in hepatitis B inactive carriers and patients with past HBV infection
- Conditions
- Rheumatoid Arthritis, Hepatitis B Reactivation, Exposure to Hepatitis B Virus
- Trial name
- NCT01907230
- Testing
- Entecavir
- Where
- Taiwan
- Volunteers
- 115 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
HBV Carrier
Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration
Hepatocellular carcinoma (HCC) is a very severe disease in Taiwan caused 7,000 deaths per year, and majorly about 70% is caused by the chronic hepatitis B virus infection.
- Trial name
- NCT02953600
- Testing
- Standard Dose Spirulina Platensis, Zero Spirulina Platensis, Double Dose Spirulina Platensis
- Where
- Taiwan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B virus carriers
- Conditions
- Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas, Chronic Hepatitis B, Lymphoma, Small Lymphocytic
- Trial name
- NCT02991638
- Testing
- Ibrutinib
- Where
- Hong Kong
- Volunteers
- 62 people
- Sponsor
- The University of Hong Kong
Chronic Hepatitis B
Health Promotion and Management for Hepatitis B Carriers
The investigators propose a project of preventive medicine with concern of local context in Taiwan. The target population includes all staff and faculty members, students, and alumni of a university in Northern Taiwan, with…
- Trial name
- NCT01065363
- Testing
- standardized exercise program and dietary counseling
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis B
Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy
A single center, randomized controlled trial design was used to select patients with chronic hepatitis B in the immune control period (HBsAg positive, HBeAg negative, normal ALT, HBsAg ≤ 1500iu/ml, HBV DNA ≤ 2000iu/ml) to enter…
- Trial name
- NCT05451420
- Testing
- PegIFN α- 2b
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Henan Provincial People's Hospital
Hepatitis B, Chronic
A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine
A single center, open labeled phase I/IIa study to evaluate safety, tolerability and efficacy of a therapeutic hepatitis B vaccine in oral antiviral drug-treated chronic hepatitis B virus carriers
- Trial name
- NCT02693652
- Testing
- CVI-HBV-002
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Aribio Lab Co., Ltd.
Hepatitis B, Chronic, Tumor
Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy
To evaluate the effectiveness and safety of tenofovir for different treatment duration in preventing HBV relapse in patients with malignancies after receiving chemotherapy and off-treatment of chemotherapy.
- Trial name
- NCT02081469
- Testing
- TDF
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Chang Gung Memorial Hospital
Gastrointestinal Cancers
Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers
There has been no report on whether the patients with gastrointestinal cancer who are also inactive hepatitis B carriers should receive prophylactic use or preemptive use of an anti-viral drug entecavir during anti-tumor therapy.
- Trial name
- NCT06966232
- Testing
- Entecavir
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Sun Yat-sen University
Hepatitis B
Coexistence HBsAg/HBcAC, Clinical Characterístics & Outcomes
HBV infection is a dynamic process with complex interactions between virus replication and the host's immune response. The appearance of anti-HBs after HBV infection generally indicates recovery and immunity to HBV1 infection.
- Trial name
- NCT05446532
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Corporacion Parc Tauli